Growth Opportunities in AI and GLP-1 will Drive the Expansion of Type 2 Diabetes Devices
This study provides a detailed overview of the global diabetes care device industry, which is witnessing a significant increase in demand due to the growing prevalence of diabetes across regions.
The market, comprising both established players and emerging start-ups, is the site of fierce competition. OEMs are developing innovative, AI-equipped technology to enhance diabetes care and expand the customer base beyond patients with type 1 diabetes (T1D) to those with type 2 diabetes (T2D), prediabetes, and even those without diabetes. Companies are adopting novel business strategies that create steady revenue streams and ease patients' financial burdens.
The study segments diabetes care devices into two main categories: glucose monitoring and insulin delivery. Glucose monitoring devices comprise self-monitoring of blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems, while insulin delivery devices comprise insulin pumps and insulin pens. The study also segments the industry according to diabetes type (T1D and T2D), examining the unique market dynamics of each.
The geographic scope includes North America, Europe, Asia-Pacific (APAC), the Middle East, Africa, and South Asia (MEASA), and Latin America. The study provides relevant forecast, sizing, and trend analyses across all segments. It examines the competitive landscape and highlights the key players and significant technologies making an impact in this space.
The study identifies the factors driving and restraining growth in each segment and analyzes the opportunities emerging from the changes in this industry for market players and stakeholders to leverage. The base year is 2023, and the forecast period is from 2024 to 2028.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Diabeloop
- Decide Clinical Software
